Short-Term and Medium-Term Clinical Outcomes of Quinolone-Resistant Campylobacter Infection

被引:14
作者
Evans, Meirion R. [1 ,2 ]
Northey, Gemma [2 ]
Sarvotham, Tinnu S. [2 ]
Rigby, Christine J. [2 ]
Hopkins, A. Lynne [2 ]
Thomas, Daniel Rh. [1 ]
机构
[1] Natl Publ Hlth Serv Wales, Ctr Communicable Dis Surveillance, Cardiff CF10 3NW, S Glam, Wales
[2] Cardiff Univ, Dept Publ Hlth & Primary Care, Cardiff, S Glam, Wales
关键词
CIPROFLOXACIN RESISTANCE; JEJUNI INFECTIONS; DIARRHEA; CONSEQUENCES; DURATION; RISKS;
D O I
10.1086/598932
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Campylobacter species is a leading cause of bacterial gastroenteritis worldwide. Quinolone resistance has emerged as an increasing problem among persons with Campylobacter infection over the past decade, but the clinical consequences are unclear. Methods. A case-comparison study of patients infected with ciprofloxacin-resistant or ciprofloxacin-susceptible Campylobacter species was conducted in Wales during the period 2003-2004. Campylobacter isolates were classified as resistant or susceptible to ciprofloxacin on the basis of standardized disk diffusion methods. Participants were interviewed by telephone at the time of illness, 3 months later, and 6 months later to compare disease severity, duration of illness, and medium-term clinical outcomes. Results. There was no difference between 145 persons with ciprofloxacin-resistant infection and 411 with ciprofloxacin-susceptible infection with regard to the severity or duration of acute illness. Mean duration of diarrhea was similar in patients with ciprofloxacin-resistant versus ciprofloxacin-susceptible infection (8.2 vs. 8.6 days; P = .57) and did not alter significantly after adjustment for potential covariates, including age, underlying disease, foreign travel, use of antidiarrheal medication, and use of antimicrobials in a multiple linear regression model. There was no difference between case patients and comparison patients in the frequency of reported symptoms or in general practitioner consultation rates at either the 3-month or the 6-month follow-up interview. Conclusions. In this study, there was no evidence of more-severe or prolonged illness in participants with quinolone-resistant Campylobacter infection, nor was there evidence of any adverse medium-term consequences. This suggests that the clinical significance of quinolone resistance in Campylobacter infection may have been overestimated.
引用
收藏
页码:1500 / 1506
页数:7
相关论文
共 24 条
  • [1] Ciprofloxacin resistance in Campylobacter jejuni:: case-case analysis as a tool for elucidating risks at home and abroad
    Charlett, A
    Cowden, JM
    Frost, JA
    Gillespie, IA
    Millward, J
    Neal, KR
    O'Brien, JSJ
    Painter, MJ
    Syed, Q
    Tompkins, D
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (04) : 561 - 568
  • [2] Cox LA, 2005, J INFECT DIS, V191, P1565
  • [3] Quinolone-resistant Campylobacter infections in Denmark:: Risk factors and clinical consequences
    Engberg, J
    Neimann, J
    Nielsen, EM
    Aarestrup, FM
    Fussing, V
    [J]. EMERGING INFECTIOUS DISEASES, 2004, 10 (06) : 1056 - 1063
  • [4] Quinolone and macrolide resistance in Campylobacter jejuni and C-coli:: Resistance mechanisms and trends in human isolates
    Engberg, J
    Aarestrup, FM
    Taylor, DE
    Gerner-Smidt, P
    Nachamkin, I
    [J]. EMERGING INFECTIOUS DISEASES, 2001, 7 (01) : 24 - 34
  • [5] Practice guidelines for the management of infectious diarrhea
    Guerrant, RL
    Van Gilder, T
    Steiner, TS
    Thielman, NM
    Slutsker, L
    Tauxe, RV
    Hennessy, T
    Griffin, PM
    DuPont, H
    Sack, RB
    Tarr, P
    Neill, M
    Nachamkin, I
    Reller, LB
    Osterholm, MT
    Bennish, ML
    Pickering, LK
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) : 331 - 351
  • [6] Adverse health events associated with antimicrobial drug resistance in Campylobacter species:: A registry-based cohort study
    Helms, M
    Simonsen, J
    Olsen, KEP
    Molbak, K
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (07) : 1050 - 1055
  • [7] *HLTH PROT AG, 2007, ANT RES ENGL WAL NO
  • [8] *HPA, CAMP SPP LAB REP FAE
  • [9] Recommendations for susceptibility tests on fastidious organisms and those requiring special handling
    King, A
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 : 77 - 80
  • [10] KIST M, 2002, INT J INFECT DIS S3, V6